Stuart A Rushworth - JoVE Visualize

Showing results (41-50 of 72) with videos related to

Pageof 8

Sort By:

Blood|October 19, 2012

The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistanceStuart A Rushworth, Lyubov Zaitseva, Megan Y Murray, et al.

Cellular Signalling|September 15, 2012

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κBStuart A Rushworth, Kristian M Bowles, Lawrence N Barrera, et al.

Molecules (Basel, Switzerland)|December 17, 2024

Increased Trypanocidal Activity of the Salinomycin Derivative Ironomycin Is Due to ROS Production and Iron Uptake ImpairmentDietmar Steverding, Stuart A Rushworth, Georgina R Hurle, et al.

Biochemical Society Transactions|August 12, 2014

Understanding life and death decisions in human leukaemiasDavid J MacEwan, Lawrence N Barrera, Sujitra Keadsanti, et al.

Scientific Reports|August 22, 2015

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemiaGenevra Pillinger, Amina Abdul-Aziz, Lyubov Zaitseva, et al.

Experimental Parasitology|March 21, 2024

Suramin: Effectiveness of analogues reveals structural features that are important for the potent trypanocidal activity of the drugDietmar Steverding, Ryan A J Tinson, Monica Piras, et al.

Cell Cycle (Georgetown, Tex.)|January 8, 2015

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myelomaMegan Y Murray, Lyubov Zaitseva, Martin J Auger, et al.

Oncotarget|October 9, 2014

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AMLLyubov Zaitseva, Megan Y Murray, Manar S Shafat, et al.

Biomarker Research|May 14, 2021

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid LeukemiaJayna J Mistry, Charlotte Hellmich, Amelia Lambert, et al.

Journal of Hematology & Oncology|May 18, 2018

Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYCRachel E Piddock, Christopher R Marlein, Amina Abdul-Aziz, et al.

Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:

Pageof 8

Blood|October 19, 2012

The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistanceStuart A Rushworth, Lyubov Zaitseva, Megan Y Murray, et al.

Cellular Signalling|September 15, 2012

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κBStuart A Rushworth, Kristian M Bowles, Lawrence N Barrera, et al.

Molecules (Basel, Switzerland)|December 17, 2024

Increased Trypanocidal Activity of the Salinomycin Derivative Ironomycin Is Due to ROS Production and Iron Uptake ImpairmentDietmar Steverding, Stuart A Rushworth, Georgina R Hurle, et al.

Biochemical Society Transactions|August 12, 2014

Understanding life and death decisions in human leukaemiasDavid J MacEwan, Lawrence N Barrera, Sujitra Keadsanti, et al.

Scientific Reports|August 22, 2015

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemiaGenevra Pillinger, Amina Abdul-Aziz, Lyubov Zaitseva, et al.

Experimental Parasitology|March 21, 2024

Suramin: Effectiveness of analogues reveals structural features that are important for the potent trypanocidal activity of the drugDietmar Steverding, Ryan A J Tinson, Monica Piras, et al.

Cell Cycle (Georgetown, Tex.)|January 8, 2015

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myelomaMegan Y Murray, Lyubov Zaitseva, Martin J Auger, et al.

Oncotarget|October 9, 2014

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AMLLyubov Zaitseva, Megan Y Murray, Manar S Shafat, et al.

Biomarker Research|May 14, 2021

Venetoclax and Daratumumab combination treatment demonstrates pre-clinical efficacy in mouse models of Acute Myeloid LeukemiaJayna J Mistry, Charlotte Hellmich, Amelia Lambert, et al.

Journal of Hematology & Oncology|May 18, 2018

Myeloma-derived macrophage inhibitory factor regulates bone marrow stromal cell-derived IL-6 via c-MYCRachel E Piddock, Christopher R Marlein, Amina Abdul-Aziz, et al.

Pageof 8